The 30-second summary
- Two 2026 studies found GLP-1 use linked to a meaningful drop in obesity-related cancers: about a 41% lower risk overall, and around 30% lower breast cancer risk in women, in people with obesity but without diabetes.
- The likely reason is not magic. It is losing excess fat and lowering inflammation, both of which are well-established drivers of these cancers.
- These are observational findings: strong enough to be hopeful, not strong enough to take a drug for. They are one more reason to think beyond the scale, not a reason to change your medical decisions on your own.
The headline, and the honest version
If you have seen "Ozempic linked to lower cancer risk" in your feed, the studies behind it are real and worth understanding, calmly.
An observational study published in Annals of Oncology followed adults with obesity but without diabetes, and found that those using GLP-1 medications had a 41% lower risk of obesity-related cancers over an average of two years. A separate large analysis found anyone on these drugs were about 30% less likely to develop breast cancer. Among gynaecological cancers, the drop in endometrial (womb) cancer, one of the cancers most tightly linked to excess weight, was especially large.
That is genuinely encouraging news, particularly for women, since breast and endometrial cancer are among the cancers most strongly tied to body weight.
Why this is biologically believable
This is not a mysterious drug effect. It lines up with decades of cancer research.
Excess body fat is one of the best-established cancer risk factors there is. Fat tissue is not inert: it produces oestrogen and fuels low-grade, body-wide inflammation, and both feed the growth of cancers like breast and endometrial. Reduce the excess fat, and you turn down the signals that help those cancers start.
So the most likely explanation is the straightforward one: these drugs cause meaningful, sustained weight loss, and losing excess fat lowers a risk that excess fat was raising. Interestingly, in the data, tirzepatide (Mounjaro, Zepbound) was associated with a larger reduction than semaglutide, which fits, since it tends to produce more weight loss.
Read this part before you over-read the headline
Three honest caveats, because this is exactly the kind of finding that gets stretched too far:
1. Observational is not proof. These studies follow large groups and look for patterns. They are good at spotting links, but they cannot prove the drug caused the lower risk. Other differences between people who take these drugs and people who do not can muddy the picture. The researchers themselves call for longer trials to confirm it.
2. "Lower risk" is not "no risk." A 30% reduction across a population is significant for public health. It does not mean any individual is protected, and it changes nothing about ordinary screening. Keep your mammograms and check-ups exactly as your doctor advises.
3. This is not a reason to start, stop, or stay on a drug by yourself. A possible cancer-risk benefit is a fascinating bonus, not a prescribing reason, and not something to weigh without your doctor. (There are also specific cancer-related cautions, such as a thyroid-cancer note on the labels: see GLP-1s and your thyroid.)
The real takeaway for women
The useful lesson here is the same one that keeps surfacing in 2026: the benefits of these drugs that you cannot see on a scale may be the most important ones. Lower cancer risk sits alongside a proven drop in heart attacks and strokes, and early signals on slower biological ageing. The weight is the visible part. The protection happening underneath is the quieter, bigger story.
That is also the case for treating the year you spend on a GLP-1 as something to do well, not just to endure for a number. Protecting your muscle, eating enough protein, and staying consistent are not only about how you look. They are how you hold onto the deeper health gains the scale never shows you.
What to do with this
This is a screening and surveillance conversation with your clinician. The nutrition part is unchanged and unglamorous: protein first, fibre and fluid together, and a deficit that does not outrun what your body can spare.
Sources
- GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. Annals of Oncology 2026. Annals of Oncology
- Penn Medicine. GLP-1 use linked to lower breast cancer incidence in large cohort study. 2026. Penn Medicine
- World Cancer Research Fund / AICR. Body fatness and weight gain and the risk of cancer (continuous update project). WCRF
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023. NEJM
Medical disclaimer: Articles in the foodose research library are educational, not medical advice. These findings are observational and do not change cancer-screening or medication decisions, which belong with your doctor. See our full medical disclaimer.